Immunome leverages the information stored in memory B cells to guide our discovery of first-in-class antibody therapeutics directed at potentially novel targets. Our Approach Leverages broad and deep interrogation of “highly-educated” B cells from patients who have learned how to fight off their disease. Enables the simultaneous discovery of novel … Read More
Location: United States, Pennsylvania, Exton
Total raised: $25.5M
Investors 2
| Date | Name | Website |
| 09.07.2021 | Robin Hood... | robinhoodv... |
| - | BioAdvance | bioadvance... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 01.08.2020 | - | $13.3M | - |
| 10.10.2016 | Series A | $12.2M | - |
Mentions in press and media 6
| Date | Title | Description |
| 15.12.2025 | Stocks making the biggest moves midday: Zillow, KLA, iRobot, Immunome & more | - |
| 03.07.2023 | Startup led by former Seagen CEO Clay Siegall merges with public company in $125M deal | Clay Siegall. (Seagen Photo) Morphimmune, a biotech company led by former Seagen CEO Clay Siegall, is merging with a public biotech company, Immunome, in a deal boosted with $125 million from private investors. Siegall will serve as CEO, pr... |
| 20.05.2021 | IMMUNOME, INC. Immunome : Announces Additional $4.3 Million Award by DOD following Positive Preclinical Testing Results on COVID-19 Variants of Concern (Form 8-K) | Immunome Announces Additional $4.3 Million Award by DOD following Positive Preclinical Testing Results on COVID-19 Variants of Concern - Additional $4.3 million in funding brings total DOD funding to $17.6 million. - Antibody cocktail (IMM-... |
| 20.05.2021 | IMMUNOME, INC. Immunome : Announces Additional $4.3 Million Award by DOD following Positive Preclinical Testing Results on COVID-19 Variants of Concern | Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell discovery engine platform to discover and develop first-in-class antibody therapeutics, today announced a $4.3 million increase awarded by the ... |
| 23.03.2021 | Immunome Advances Its Proprietary Antibody Against IL-38, a Novel Innate Immune Checkpoint, into IND-enabling Studies | EXTON, Pa.--(BUSINESS WIRE)--Mar 23, 2021-- Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced that it adva... |
| 10.10.2016 | Immunome Raises $12.2M in Additional Series A Financing | Immunome, Inc., a Philadelphia, PA-based biotechnology company focused on developing immunotherapies to treat cancer, raised $12.2M in additional Series A financing. The deal included: – an aggregate of $10.2m in 2016 Series A Preferred Sto... |